Skip to main content
Equibles
EBS logo

EBS · Emergent BioSolutions Inc.

Track EBS — free

Use EBS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.21 -0.02 (-0.32%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$318.41M
Shares
51.27M

EBS metrics

76 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.21
Market cap
$318.41M

Price action

19 metrics
Price change (1W)
+5.1%
Price change (30D)
+16.9%
Price change (3M)
-23.0%
Price change (6M)
-25.1%
Price change (YTD)
-49.8%
Price change (1Y)
-18.6%
Trailing year
Price change (5Y)
-90.2%
52-week high
$13.90
52-week low
$4.45
Change from 52-week high
-55.3%
Change from 52-week low
+39.6%
Annualized volatility
78.5%
Beta
1.2
RSI (14D)
54.3
Price vs SMA 50
-7.2%
Price vs SMA 200
-31.3%
Avg volume (3M)
1.08M
Relative volume
0.9
Average dollar volume
$7.03M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
51.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 232.5%
P / book
1.0
reciprocal yield 103.1%
FCF yield
25.9%
TTM · current market cap
Buyback yield
10.9%
P / FCF
3.9
reciprocal yield 25.9%
P / operating cash flow
3.4
reciprocal yield 29.5%
Earnings yield
-53.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
11.7×
reciprocal yield 8.5%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 106.0%
EV / revenue historical average (5Y)
1.0×
reciprocal yield 97.2%
EV / EBIT historical average (3Y)
10.0×
reciprocal yield 10.0%
EV / EBIT historical average (5Y)
9.3×
reciprocal yield 10.8%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
10.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-8.6%
Trailing 12 months
Net margin
-23.0%
Gross profit (TTM)
$345.80M
Operating profit (TTM)
−$66.00M
Net income (TTM)
−$176.80M
Trailing 12 months
Diluted EPS (TTM)
$-3.46
FCF margin
11.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$16.03

Growth

11 metrics
Revenue growth YoY
+66.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$770.20M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-4.8%
Year over year · fewer shares
Revenue CAGR (3Y)
-12.7%
Revenue CAGR (5Y)
-14.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-30.4%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-16.9%

Quality

14 metrics
Return on equity
-51.8%
Return on assets
-15.8%
Debt / equity
—
Current ratio
5.4
EBITDA (TTM)
$28.40M
Free cash flow (TTM)
$85.90M
Quick ratio
3.0
Interest coverage
-1.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$139.70M
Total assets
$1.12B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$97.70M
Capital expenditures (TTM)
$11.80M
R&D (TTM)
$45.30M
SG&A (TTM)
$181.20M
Stock compensation (TTM)
$18.90M
R&D / revenue
5.9%
Stock compensation / revenue
2.5%

Ownership (13F)

3 metrics
13F filers
197
13F filer change QoQ
+5
Institutional ownership
86.1%

Short interest

3 metrics
Short interest
22.7%
Latest settlement · 6.0 days to cover
Days to cover
6.0d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$25,200
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1367644 CUSIP 29089Q105 13F (30d) 155 filings 155 filers Visit website Investor relations